- Reunion (REUN) has appointed Edward Smith as the company’s Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately
- Smith is an industry veteran with more than 20 years of financial management experience
- Dr. Asnis-Alibozek is a Board-certified physician assistant and graduate of the Yale School of Medicine
- Reunion (formerly Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions
- Reunion Neuroscience Inc. (REUN) is down 11.52 per cent, trading at C$2.15 per share at 3:07 pm ET
Reunion (REUN) has appointed Edward Smith as the company’s Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately.
Both Smith and Asnis-Alibozek will report to Greg Mayes, Reunion’s President and CEO.
Smith is an industry veteran with more than 20 years of financial management experience. He has served as CFO of several publicly traded, clinical-stage biotechnology companies. Prior to joining Reunion, Smith was CFO and took public LAVA Therapeutics N.V., Marinus Pharmaceuticals, Inc. and PolyMedix, Inc. Prior to that, he was executive director of finance at InKine Pharmaceutical Company, Inc. He assisted with the acquisition of that company by Salix Pharmaceuticals, Inc.
He is currently a member of the board of directors at Benitec Biopharma, Inc. He holds a B.S. in business administration from the University of Hartford and was licensed as a Certified Public Accountant in Pennsylvania.
Dr. Asnis-Alibozek is a Board-certified physician assistant and graduate of the Yale School of Medicine. She obtained a specialized Master of Physician Assistant Studies degree in oncology and was appointed a Distinguished Fellow of the American Academy of Physician Assistants.
Prior to joining Reunion, Dr. Asnis-Alibozek served as a medical affairs and clinical and commercial development consultant at Viva Bio Pharma Services, LLC. Prior to that, she served as Executive Vice President of Global Medical Affairs at TRM Oncology, a division of Aptitude Health. Earlier in her career, she held various industry positions at AstraZeneca Pharmaceuticals, Pharmacia Corporation, IBA Molecular, Inc. and Research to Practice. Dr. Asnis-Alibozek earned her Doctor of Medical Science degree in the advanced professional practice of administrative medicine from the University of Lynchburg.
Reunion (formerly Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions.
Reunion Neuroscience Inc. (REUN) is down 11.52 per cent, trading at C$2.15 per share at 3:07 pm ET.
